Genovate Biotechnology Co Ltd Cash Flow-to-Debt Ratio
Genovate Biotechnology Co Ltd cash flow-to-debt ratio. Genovate Biotechnology Co Ltd (4130) has a Cash Flow-to-Debt Ratio of 0.13x as of December 2025, meaning its operating cash flow of NT$16.93 Million could theoretically repay 0% of its total liabilities (NT$126.05 Million) in one year. Check 4130 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Genovate Biotechnology Co Ltd (2015–2025)
Cash flow-to-debt ratio of Genovate Biotechnology Co Ltd from 2015 to 2025. Historical debt coverage capacity for Genovate Biotechnology Co Ltd across 11 annual periods. Check 4130 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Genovate Biotechnology Co Ltd Cash Flow-to-Debt Ratio by Year (2015–2025)
Genovate Biotechnology Co Ltd cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Genovate Biotechnology Co Ltd. For the full cash flow conversion analysis, see 4130 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.35x | NT$43.79 Million | NT$126.05 Million | ▼ -11.1% |
| 2024 | 0.39x | NT$55.11 Million | NT$141.08 Million | ▼ -39.3% |
| 2023 | 0.64x | NT$84.78 Million | NT$131.69 Million | ▲ +6449.1% |
| 2022 | 0.01x | NT$1.51 Million | NT$153.60 Million | ▲ +107.8% |
| 2021 | -0.13x | NT$-17.26 Million | NT$136.65 Million | ▼ -121.0% |
| 2020 | 0.60x | NT$87.08 Million | NT$144.87 Million | ▲ +122.8% |
| 2019 | 0.27x | NT$44.43 Million | NT$164.68 Million | ▼ -26.1% |
| 2018 | 0.36x | NT$62.88 Million | NT$172.32 Million | ▲ +415.8% |
| 2017 | 0.07x | NT$31.27 Million | NT$442.06 Million | ▼ -60.2% |
| 2016 | 0.18x | NT$70.58 Million | NT$397.04 Million | ▲ +114.7% |
| 2015 | 0.08x | NT$32.53 Million | NT$392.95 Million | — |